TrialScope, the global leader in clinical trial transparency and compliance solutions announced the launch of its newest solution, Core Disclosure.Promoting a new level of data efficiency accuracy and alignment, Core Disclosure enables teams to approve disclosure content once and then reuse the disclosure data around the globe.

mProve Health, a leading provider of mobile technologies for patient engagement and electronic clinical outcome assessments (eCOA), andGreenphire, the global leader in clinical payment automation, today announceda partnership to provide patients with real-time access to ClinCard payment detailsvia mProve’s engagement app, mPal.

Schmolz + Bickenbach Announces $49.96 Million Investment in Swiss Steel

Clinerion has filed an international patent application following the PCT route for a new technology for patient search and identification based on the electronic medical records of patients held by hospitals. The “anonymized identification” (ANID) technology involves exclusively the use of anonymized data, ensuring the privacy and security of patient information.

Schmolz + Bickenbach Announces $49.96 Million Investment in Swiss Steel

Biotage ,a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, is pleased to announce the launch of Isolera™ Dalton 2000, a new mass detector for flash purification that expands functionality through a wider detection range of ion masses, up to m/z 2000, and new analysis features.

Lonza has introduced the CytoSMART 2 System, an updated version of Lonza’s popular CytoSMART System for live cell imaging. The CytoSMART 2 Device features an advanced optical system and more powerful camera unit, which enables researchers to capture higher-resolution images of their cell cultures.

Biotage , a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, is pleased to announce the launch of EVOLUTE HYDRO, solid phase extraction plates with an integral Hydrolysis capability that enable chemists to perform sample hydrolysis within the extraction plate; saving time and reducing sample transfer issues.

Aptar Pharma, a world leader in innovative drug delivery systems, is pleased to announce the approval by the EMA of the first integrated electronic nasal lockout device (e-Lockout) following a multi-year development with Takeda Pharmaceuticals International AG.